{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T22:57:14Z","timestamp":1776293834834,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clnu.2014.08.010","type":"journal-article","created":{"date-parts":[[2014,8,31]],"date-time":"2014-08-31T00:19:51Z","timestamp":1409444391000},"page":"727-731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy"],"prefix":"10.1016","volume":"34","author":[{"given":"Divair","family":"Doneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 L.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno C.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana D.","family":"Mittelstadt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cileide C.","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida V.D.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clnu.2014.08.010_bib1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.12804","article-title":"Gaucher disease: haematological presentations and complications","volume":"165","author":"Thomas","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clnu.2014.08.010_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Crit Rev Oncog"},{"issue":"7","key":"10.1016\/j.clnu.2014.08.010_bib3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21721","article-title":"Hyperferritinemia and iron overload in type 1 Gaucher disease","volume":"85","author":"Stein","year":"2010","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clnu.2014.08.010_bib4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/0026-0495(89)90165-0","article-title":"Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements","volume":"38","author":"Barton","year":"1989","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.clnu.2014.08.010_bib5","first-page":"2653","article-title":"Increased basal glucose production in type 1 Gaucher's disease","volume":"80","author":"Corssmit","year":"1995","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.clnu.2014.08.010_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bcmd.2010.10.008","article-title":"Gaucher disease type I: assessment of basal metabolic rate in patients from southern Brazil","volume":"46","author":"Doneda","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clnu.2014.08.010_bib7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.metabol.2006.10.014","article-title":"Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia","volume":"56","author":"Langeveld","year":"2007","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.clnu.2014.08.010_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9343(97)00134-4","article-title":"Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease","volume":"103","author":"Hollak","year":"1997","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.clnu.2014.08.010_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1210\/jc.2007-1702","article-title":"Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance","volume":"93","author":"Langeveld","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.clnu.2014.08.010_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ymgme.2008.10.001","article-title":"A\u00a0cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight","volume":"96","author":"Ucar","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"10.1016\/j.clnu.2014.08.010_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbalip.2007.11.004","article-title":"Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention","volume":"1781","author":"Groener","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"1\u20132","key":"10.1016\/j.clnu.2014.08.010_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2007.12.001","article-title":"Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease","volume":"389","author":"Ghauharali-van der Vlugt","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.clnu.2014.08.010_bib13","first-page":"1","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy","volume":"17","author":"Langeveld","year":"2008","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"10.1016\/j.clnu.2014.08.010_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1743-7075-10-34","article-title":"Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review","volume":"10","author":"Doneda","year":"2013","journal-title":"Nutr Metab (Lond)"},{"key":"10.1016\/j.clnu.2014.08.010_bib15","series-title":"New clinical genetics, 2nd revised edition","author":"Read","year":"2010"},{"key":"10.1016\/j.clnu.2014.08.010_bib16","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2014.08.010_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1475-2840-7-35","article-title":"Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study","volume":"7","author":"Ford","year":"2008","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.clnu.2014.08.010_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jpeds.2007.08.010","article-title":"Examining metabolic syndrome definitions in overweight hispanic youth: a focus on insulin resistance","volume":"152","author":"Shaibi","year":"2008","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.clnu.2014.08.010_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cca.2006.07.005","article-title":"Molecular mechanisms of insulin resistance and associated diseases","volume":"375","author":"Mlinar","year":"2007","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.clnu.2014.08.010_bib20","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","article-title":"Inflammation and insulin resistance","volume":"116","author":"Shoelson","year":"2006","journal-title":"J\u00a0Clin Invest"},{"issue":"7121","key":"10.1016\/j.clnu.2014.08.010_bib21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.clnu.2014.08.010_bib22","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cell.2012.02.017","article-title":"Integrating mechanisms for insulin resistance: common threads and missing links","volume":"148","author":"Samuel","year":"2012","journal-title":"Cell"},{"issue":"6762","key":"10.1016\/j.clnu.2014.08.010_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clnu.2014.08.010_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yfrne.2009.10.008","article-title":"Ghrelin in the regulation of body weight and metabolism","volume":"31","author":"Casta\u00f1eda","year":"2010","journal-title":"Front Neuroendocrinol"},{"issue":"2","key":"10.1016\/j.clnu.2014.08.010_bib25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mce.2009.08.018","article-title":"Adipose tissue as an endocrine organ","volume":"316","author":"Galic","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"10.1016\/j.clnu.2014.08.010_bib26","doi-asserted-by":"crossref","first-page":"e45657","DOI":"10.1371\/journal.pone.0045657","article-title":"Serum acylated ghrelin is negatively correlated with the insulin resistance in the CODING study","volume":"7","author":"Amini","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clnu.2014.08.010_bib27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11894-012-0291-3","article-title":"Gastric peptides and their regulation of hunger and satiety","volume":"14","author":"Stengel","year":"2012","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.clnu.2014.08.010_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semnephrol.2012.12.008","article-title":"The adipose tissue as an endocrine organ","volume":"33","author":"Adamczak","year":"2013","journal-title":"Semin Nephrol"},{"issue":"2","key":"10.1016\/j.clnu.2014.08.010_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00795-007-0366-7","article-title":"Pathophysiological significance of adiponectin","volume":"40","author":"Nishida","year":"2007","journal-title":"Med Mol Morphol"},{"issue":"2","key":"10.1016\/j.clnu.2014.08.010_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2183\/pjab.86.131","article-title":"Establishment of a concept of visceral fat syndrome and discovery of adiponectin","volume":"86","author":"Matsuzawa","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"1","key":"10.1016\/j.clnu.2014.08.010_bib31","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.3945\/ajcn.2009.28449C","article-title":"Adiponectin in insulin resistance: lessons from translational research","volume":"91","author":"Ziemke","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2014.08.010_bib32","article-title":"Obesity: preventing and managing the global epidemic. Report a WHO consultation","author":"WHO World Health Organization","year":"2000"},{"key":"10.1016\/j.clnu.2014.08.010_bib33","series-title":"The IDF consensus worldwide definition of the metabolic syndrome","author":"International Diabetes Federation \u2013 IDF","year":"2005"},{"key":"10.1016\/j.clnu.2014.08.010_bib34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.clnu.2014.08.010_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1590\/S0004-27302009000200020","article-title":"HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome \u2013 Brazilian metabolic syndrome study (BRAMS)","volume":"53","author":"Geloneze","year":"2009","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"34","key":"10.1016\/j.clnu.2014.08.010_bib36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10545-010-9271-7","article-title":"Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity","volume":"2","author":"Stein","year":"2011","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.clnu.2014.08.010_bib37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2337\/diabetes.50.4.707","article-title":"Circulating ghrelin levels are decreased in human obesity","volume":"50","author":"Tschop","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.clnu.2014.08.010_bib38","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/jcem.87.6.8738","article-title":"Food fails to suppress ghrelin levels in obese humans","volume":"87","author":"English","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.clnu.2014.08.010_bib39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.repc.2012.08.002","article-title":"Relationship between leptin and body mass and metabolic syndrome in an adult population","volume":"31","author":"Martins","year":"2012","journal-title":"Rev Port Cardiol"},{"issue":"3","key":"10.1016\/j.clnu.2014.08.010_bib40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated","volume":"122","author":"Boven","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clnu.2014.08.010_bib41","unstructured":"Vigitel Brazil 2013: Protective and risk factors for chronic diseases by telephone survey. www.saude.gov.br\/bvs."},{"key":"10.1016\/j.clnu.2014.08.010_bib42","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1186\/1471-2458-13-1198","article-title":"Prevalence of metabolic syndrome in Brazilian adults: a systematic review","volume":"13","author":"de Carvalho Vidigal","year":"2013","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.clnu.2014.08.010_bib43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1074\/jbc.M113.522847","article-title":"Ceramides and glucosylceramides are independent antagonists of insulin signaling","volume":"289","author":"Chavez","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clnu.2014.08.010_bib44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4614-0650-1_7","article-title":"Glycosphingolipids and insulin resistance","volume":"721","author":"Aerts","year":"2011","journal-title":"Adv Exp Med Biol"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561414002167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561414002167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T14:09:10Z","timestamp":1565791750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561414002167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0261561414002167"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2014.08.010","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ghrelin, leptin and adiponectin levels in Gaucher disease type I patients on enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2014.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.","name":"copyright","label":"Copyright"}]}}